Redefining clinical trials in oncology and rare diseases across the Europe
At two upcoming events, experts will offer practical solutions to key challenges for oncology and rare disease clinical trials.
Orphan Designated Drugs
Can rare disease research in the US thrive under the new administration?
ASH 2024 discussions shine spotlight on advances in haemophilia treatments
Beyond approval: Patients pursue alternate paths to get rare disease treatments
Certa plans pivotal scleroderma trial after Phase II data readout
How orphan designated drugs M&A performed in the pharmaceutical industry in Q3 2024
How orphan designated drugs private equity performed in the pharmaceutical industry in Q3 2024
How did the pharmaceutical industry treat orphan designated drugs in Q2 2024 filings?
